Core Viewpoint - Telo Genomics Corp. has increased its non-brokered private placement of secured convertible debentures from $1,200,000 to $1,600,000 to support its diagnostic and prognostic test development for human diseases [1] Group 1: Offering Details - The Debentures will have a 15% annual interest rate, compounded quarterly, and will mature on December 15, 2026 [2] - Holders can convert the principal amount of the Debentures into common shares at a conversion price of $0.05 per share before the Maturity Date [2] - For every $100,000 of Debentures issued, the company will issue 2 million Detachable Warrants, each exercisable at $0.08 per share for 12 months [2] Group 2: Financial Proceeds - The company previously closed an initial tranche of the offering, raising $840,000 by issuing Debentures and 16,800,000 Warrants [3] - The company plans to close one or two additional tranches for up to $760,000, with the final tranche expected by March 6, 2026 [3] - Net proceeds from the Upsized Offering will be allocated for working capital and general corporate purposes [4] Group 3: Regulatory and Compliance - All securities issued will be subject to a statutory hold period of four months and one day from the issuance date, in line with Canadian securities laws [4] - The Upsized Offering is contingent upon receiving necessary regulatory approvals, including from the TSX Venture Exchange [4] Group 4: Company Overview - Telo Genomics is a biotech company focused on developing diagnostic solutions through telomere analysis, with applications in oncology and neurological diseases [6] - The company’s technology has been validated in over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients [6] - The lead application, Telo-MM, aims to provide actionable information for treating Multiple Myeloma, a serious blood cancer [6]